Singh, K., Peyser, B., Trujillo, G., Milazzo, N., Savard, D., Haga, S. B., … Voora, D. (2016). Rationale and design of the SLCO1B1 genotype guided statin therapy trial. Pharmacogenomics, 17(17), 1873–1880. https://doi.org/10.2217/pgs-2016-0065

Singh, Kavisha, Bruce Peyser, Gloria Trujillo, Nicholas Milazzo, Dillon Savard, Susanne B. Haga, Michael Musty, and Deepak Voora. “Rationale and design of the SLCO1B1 genotype guided statin therapy trial.” Pharmacogenomics 17, no. 17 (November 2016): 1873–80. https://doi.org/10.2217/pgs-2016-0065.

Singh K, Peyser B, Trujillo G, Milazzo N, Savard D, Haga SB, et al. Rationale and design of the SLCO1B1 genotype guided statin therapy trial. Pharmacogenomics. 2016 Nov;17(17):1873–80.

Singh, Kavisha, et al. “Rationale and design of the SLCO1B1 genotype guided statin therapy trial.” Pharmacogenomics, vol. 17, no. 17, Nov. 2016, pp. 1873–80. Pubmed, doi:10.2217/pgs-2016-0065.

Singh K, Peyser B, Trujillo G, Milazzo N, Savard D, Haga SB, Musty M, Voora D. Rationale and design of the SLCO1B1 genotype guided statin therapy trial. Pharmacogenomics. 2016 Nov;17(17):1873–1880.